Dapsone Rx

FDA-approved drug

Dapsone is one molecule living two lives, about one hundred times apart

The same sulfone is a monitored systemic drug and a gentle acne gel, and the crossover study measured the distance between those lives: a day of maximal gel use put 415 ng.h/mL of dapsone into the blood; one 100 mg tablet put in 52,641. On the oral side sit dermatitis herpetiformis and leprosy, a blood-count calendar, and hemolysis in almost all patients. On the topical side sit acne trials of 7,300-plus patients with side effects nearly identical to the vehicle gel, honestly modest results (about 30% clear-or-minimal skin versus 21% on vehicle), and a label that dropped its G6PD testing requirement in 2008 when route-specific data arrived. Every study row below is labeled by species and by route, so neither life borrows the other's story.

  • 26studies and evidence sources in our graded table
  • 24of them human evidence, species-labeled row by row
  • 11topical-route human rows and 11 oral-route human rows, plus the one crossover study that measured both routes at once
  • 44fetch-verified citations, 100.0% peer-reviewed or government sources

Online care, from intake to delivery

Dapsone acne care, made simple

Choose your plan, complete a private medical intake, and connect with a licensed provider. If prescribed, treatment ships discreetly to your door.

Dapsone acne care catalog product image
Prescription topical treatmentPrepared after approval
Catalog image. Dispensed product and packaging may vary by pharmacy.

Your care plan includes

Everything you need to get started

From$161.10per month
Licensed providerMedical reviewIf prescribedTreatment includedAt no added costDiscreet shippingWhen you need itOrder support
Choose your planChange or cancel future refills anytime
Due today$179.10then monthly

Encrypted checkout provider review required shipping included

  1. 01
    Choose your planSelect the supply and refill preference that works for you.
  2. 02
    Complete your intakeShare your health history in our private, secure flow.
  3. 03
    Provider reviewIf appropriate, your prescription is prepared and shipped.

Prescription treatment requires an online medical evaluation. A provider will determine whether treatment is medically appropriate; approval is not guaranteed.

Key facts

  • StatusFDA-approved drug
  • Topical Cmax (7.5%, steady state)13.0 ng/mLsource
  • Topical AUC(0-24) (7.5%)282 ng.h/mLsource
  • Topical AUC(0-24) (5% BID, day 14)415 ng.h/mLsource
  • Oral AUC (single 100 mg)52,641 ng.h/mLsource
  • Oral vs topical exposureAbout 100x (label: gel is about 1% of oral)source
  • Oral Tmax4 to 8 hourssource
  • Topical steady stateReached within 7 dayssource
  • Oral urinary recoveryAbout 85% of daily intake (as metabolites)source
  • ClassSulfone (4,4'-diaminodiphenyl sulfone, DDS); antimicrobial plus anti-inflammatoryChemical referencesource
  • Molecular weight248.30 Da (C12H12N2O2S)Chemical referencesource
  • Route divideGel exposure is about 1% of a 100 mg oral dose (AUC 282 to 415 vs 52,641 ng.h/mL)Human PKsource
  • Oral half-life10 to 50 hours, average 28Human PKsource
  • Oral hemolysisDose-related, near-universal: 1 to 2 g hemoglobin loss in almost all patientsRegulatory recordsource
  • Hypersensitivity syndrome1.4% of oral-treated patients; 9.9% fatality when it occursSystematic reviewsource
  • G6PD testingOral: caution and monitoring. Topical: not required (screening requirement removed from the label in 2008)Regulatory recordsource
  • Study rows on this site26 (24 human, 1 in vitro, 1 animal), every row species- and route-labeledInternal measurementsource
  • Verified citations44 (100.0% peer-reviewed or government)Internal measurementsource

Read the full Dapsone monograph

Browse by topic

Everything on Dapsone for skin, organized the way you research it.

All guides

50 in-depth, individually cited guides.

Review-gated archive: the guides below are preserved for individual medical and source review. They are excluded from search indexing and AI citation files.

Safety 17 guides

Evidence 12 guides

Sourcing 8 guides

Dosing 8 guides

We will tell you when the evidence moves

One email when a new trial, label revision or FDA action lands, for either route. No dosing advice by email. Unsubscribe anytime.

Free. No spam, unsubscribe anytime. Your address is used for this brief and nothing else.

Start provider review